What is ZURA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ZURA?

P/E (TTM) is n/a and 52-week range is $3.15 to $7.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ZURA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ZURA?

The company profile lists net income (TTM) near $-75M, EPS (TTM) near $-0.79 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Zura Bio Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in La Jolla, California, US, 95M shares outstanding, ISIN KYG9TY5A1016 when available from company profile and filing metadata.

Zura Bio Ltd

$ZURA

Health Care · Biotechnology

IR Run Scenarios

$4.00

-3.15%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California and currently employs 40 full-time employees. The company went IPO on 2021-07-16. The company is developing three assets which have completed Phase I/Ib studies. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Employees

Website

zurabio.com/

IPO

2021-07-16

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)